drugset / Trial / NCT07236099
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
Timeline
- Start
- 2025-11-27
- Primary completion
- 2027-03
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICP-322 | Unknown | 80 mg | — |
| Subject | ICP-322 | Unknown | 120 mg | — |